103 related articles for article (PubMed ID: 17301814)
21. Analysis of JAK2(V617F) mutation in Chinese patients with myeloproliferative disorders.
Chen S; Fei H; Zhang R; Xue Y; Pan J; Wu Y; Ceng J
Am J Hematol; 2007 Jun; 82(6):458-9. PubMed ID: 17266061
[TBL] [Abstract][Full Text] [Related]
22. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
Bousquet M; Le Guellec S; Quelen C; Rigal-Huguet F; Delsol G; Brousset P
Hum Pathol; 2006 Nov; 37(11):1458-64. PubMed ID: 16949922
[TBL] [Abstract][Full Text] [Related]
23. [JAK2 mutation in myeloproliferative disorders].
Inokuchi K
Rinsho Ketsueki; 2006 Aug; 47(8):693-700. PubMed ID: 16986707
[No Abstract] [Full Text] [Related]
24. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
25. Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods.
Cankovic M; Whiteley L; Hawley RC; Zarbo RJ; Chitale D
Am J Clin Pathol; 2009 Nov; 132(5):713-21. PubMed ID: 19846812
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study.
Tondeur S; Boutruche S; Biron-Andréani C; Schved JF
Thromb Haemost; 2009 Apr; 101(4):787-9. PubMed ID: 19350131
[No Abstract] [Full Text] [Related]
27. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.
Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N
Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908
[TBL] [Abstract][Full Text] [Related]
28. A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD).
Koren-Michowitz M; Shimoni A; Vivante A; Trakhtenbrot L; Rechavi G; Amariglio N; Loewenthal R; Nagler A; Cohen Y
Leuk Res; 2008 Mar; 32(3):421-7. PubMed ID: 17698191
[TBL] [Abstract][Full Text] [Related]
29. No evidence for amplification of V617F JAK2 in myeloproliferative disorders.
Jones AV; Bunyan DJ; Cross NC
Leukemia; 2007 Dec; 21(12):2561-3. PubMed ID: 17611555
[No Abstract] [Full Text] [Related]
30. The JAK2 V617F mutation in patients with cerebral venous thrombosis: a rebuttal.
De Stefano V; Rossi E; Za T; Chiusolo P; Leone G
Thromb Haemost; 2008 Jun; 99(6):1121. PubMed ID: 18521519
[No Abstract] [Full Text] [Related]
31. Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation.
Er TK; Lin SF; Chang JG; Hsieh LL; Lin SK; Wang LH; Lin CW; Chang CS; Liu TC
Clin Chim Acta; 2009 Oct; 408(1-2):39-44. PubMed ID: 19595684
[TBL] [Abstract][Full Text] [Related]
32. Rapid real-time PCR assay for detection of MPL W515L mutation in patients with chronic myeloproliferative disorders.
Ghaderi M; Strömberg O; Porwit A
Int J Lab Hematol; 2010 Feb; 32(1 Pt 2):122-6. PubMed ID: 19016916
[TBL] [Abstract][Full Text] [Related]
33. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.
Aboudola S; Murugesan G; Szpurka H; Ramsingh G; Zhao X; Prescott N; Tubbs RR; Maciejewski JP; Hsi ED
Am J Surg Pathol; 2007 Feb; 31(2):233-9. PubMed ID: 17255768
[TBL] [Abstract][Full Text] [Related]
34. JAK2 V617F mutation associated with cerebral venous thrombosis: a report of five cases.
Godeneche G; Gaillard N; Roy L; Mania A; Tondeur S; Chomel JC; Lavabre T; Arquizan C; Neau JP
Cerebrovasc Dis; 2010 Jan; 29(2):206-9. PubMed ID: 20029191
[No Abstract] [Full Text] [Related]
35. The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms.
Trifa AP; Cucuianu A; Petrov L; Urian L; Militaru MS; Dima D; Pop IV; Popp RA
Ann Hematol; 2010 Oct; 89(10):979-83. PubMed ID: 20422415
[TBL] [Abstract][Full Text] [Related]
36. [The frequency of JAK2 V617F mutation, expression level of phosphorylated JAK/STATs proteins and their clinical significance in myeloproliferative disorders patients].
Hu GY; Deng MY; Zhang GS; Luo YY; Zhu JF
Zhonghua Xue Ye Xue Za Zhi; 2009 Jun; 30(6):394-8. PubMed ID: 19951533
[TBL] [Abstract][Full Text] [Related]
37. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.
Campbell PJ; Baxter EJ; Beer PA; Scott LM; Bench AJ; Huntly BJ; Erber WN; Kusec R; Larsen TS; Giraudier S; Le Bousse-Kerdilès MC; Griesshammer M; Reilly JT; Cheung BY; Harrison CN; Green AR
Blood; 2006 Nov; 108(10):3548-55. PubMed ID: 16873677
[TBL] [Abstract][Full Text] [Related]
38. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.
Benmoussa A; Dehbi H; Fehri S; Quessar A; Nadifi S
Pathol Biol (Paris); 2011 Aug; 59(4):e89-92. PubMed ID: 19939582
[TBL] [Abstract][Full Text] [Related]
39. Molecular insights into the morphology of myeloproliferative neoplasms using an in situ PCR assay specific for the JAK2 mutation V617F.
Gattenlohner S; Serfling E; Einsele H; Müller-Hermelink HK
Leukemia; 2009 Jan; 23(1):196-9. PubMed ID: 18580953
[No Abstract] [Full Text] [Related]
40. Accuracy of leukocyte alkaline phosphatase score to predict JAK2 V617F mutation.
Basquiera AL; Fassetta F; Soria N; Barral JM; Ricchi B; García JJ
Haematologica; 2007 May; 92(5):704-5. PubMed ID: 17488700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]